Update on glycopeptide use in German university hospitals

Infection

Volumn 32, Issue 3, 2004, Pages 157-162

  Kern, W V ^a   De With, K ^a   Gonnermann, C ^b   Strehl, E ^a   Bergner, Jobst ^c   Höffken, Gert ^c   Dörje, Frank ^c   Daschner, Franz ^c   Steib Bauert, Michaela ^c   Haber, Manfred ^c   Herrmann, Matthias ^c   Hartmann, Michael ^c   Straube, Eberhard ^c   Bühner, Reinhard ^c   Rothe, Ulrich ^c   Salzberger, Bernd ^c   Marre, Reinhard ^c   Kern, Peter ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GLYCOPEPTIDE;

CONTROLLED STUDY; DATA ANALYSIS; DRUG USE; GERMANY; HEALTH SERVICE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MEDICAL RECORD; MEDICAL SERVICE; PHARMACY; REVIEW; UNIVERSITY HOSPITAL; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG UTILIZATION; GERMANY; GLYCOPEPTIDES; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INTENSIVE CARE UNITS;

EID: 2942598362     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3159-0     Document Type: Review

References (56)

1. Cheung RPF, DiPiro JT: Vancomycin: an update. Pharmacotherapy 1986; 6: 153.
2. Campoli-Richards DM, Brogden RN, Faulds D: Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1990; 40: 449-486.
3. Jarvis WR: Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis 1998; 26: 1200-1203.
4. Pantazatou A, Papaparaskevas J, Stefanou I, Papanicolas J, Demertzi E, Avlamis A: Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in a Greek tertiary care hospital, over an 8-year period. Int J Antimicrob Agents 2003; 21: 542-546.
5. Van Griethuysen A, Van't Veen A, Buiting A, Walsh T, Kluytmans J: High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J Clin Microbiol 2003; 41: 2487-2491.
6. Kim HB, Park WB, Lee KD, Choi YJ, Park SW, Oh MD, Kim EC, Choe KW: Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea. J Clin Microbiol 2003; 41: 2279-2281.
7. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ: Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 2002; 50: 383-391.
8. Hussain FM, Boyle-Vavra S, Shete PB, Daum RS: Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002; 186: 661-667.
9. g. Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327-332.
10. Chavers LS, Moser SA, Benjamin WH, Banks SE, Steinhauer JR, Smith AM, Johnson CN, Funkhouser E, Chavers LP, Stamm AM, Waites KB: Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect 2003; 53: 159-171.
11. Bonten MJ, Willems R, Weinstein RA: Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001; 1: 314-325.
12. Ena J, Dick RW, Jones RN, Wenzel RP: The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA 1993; 269: 598-602.
13. Robertson MB, Dartnell JC, Korman TM: Vancomycin and teicoplanin use in Victorian hospitals. The Victorian Drug Usage Evaluation Group. Med J Aust 1999; 171: 127-131.
14. Lipsky BA, Baker CA, McDonald LL, Suzuki NT: Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 1999; 27: 84-91.
15. Sinkowitz RL, Keyserling H, Walker TJ, Holland J, Jarvis WR: Epidemiology of vancomycin usage at a children's hospital, 1993 through 1995. Pediatr Infect Dis J 1997; 16: 485-489.
16. Kwan T, Lin F, Ngai B, Loeb M: Vancomycin use in two Ontario tertiary care hospitals: a survey. Clin Invest Med 1999; 22: 256-264.
17. Shah SS, Sinkowitz-Cochran RL, Keyserling HL, Jarvis WR: Vancomycin use in pediatric neurosurgery patients. Am J Infect Control 1999; 27: 482-487.
18. Hopkins HA, Sinkowitz-Cochran RL, Rudin BA, Keyserling HL, Jarvis WR: Vancomycin use in pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 2000; 21: 48-50.
19. Nourse C, Byrne C, Leonard L, Butler K: Clycopeptide prescribing in a teriary referral paediatric hospital and applicability of Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines to children. Eur J Pediatr 2000; 159: 193-197
20. Wright SW, Wrenn KD: Appropriateness of vancomycin use in the emergency department. Ann Emerg Med 1998; 32: 531-536.
21. Hamilton CD, Drew R, Hayward S, Kure J, Janning S: Improving clinician adherence to vancomycin-use guidelines: results of a pharmacist-based strategy at at an academic medical center [abstract]. Clin Infect Dis 1997; 25: 425.
22. Salemi C, Becker L, Morrissey R, Warmington J: A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Clin Perform Qual Health Care 1998; 6: 12-16.
23. Johnson SV, Hoey LL, Vance-Bryan K: Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy 1995; 15: 579-585.
24. Evans ME, Kortas KJ: Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996; 17: 356-359.
25. Singer MV, Haft R, Barlam T, Aronson M, Shafer A, Sands KE: Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998; 19: 248-253.
26. Keyserling HL, Sinkowitz-Cochran RL, Harris JM 2nd, Levine CL, Siegel JD, Stover BH, Lau SA, Jarvis WR: Vancomycin use in hospitalized pediatric patients. Pediatrics 2003; 112: e104-e111.
27. Kumana CR, Ching TY, Kong Y, Ma EC, Kou M, Lee RA, Cheng VC, Chiu SS, Seto WH: Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin-resistant Staphylococcus aureus infections. Br J Clin Pharmacol 2001; 52: 427-432.
28. Fridkin SK, Edwards JR, Pichette SC, Pryor ER, McGowan JE Jr, Tenover FC, Culver DH, Gaynes RP: Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis 1999; 28: 1119-1125.
29. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Archibald LK, Gaynes RP, Tenover FC, and Project Intensive Care Antimicrobial Resistance (ICARE) Hospitals: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999; 29: 245-252.
30. Fridkin SK, Lawton R Edwards JR, Tenover FC, McGowan JE Jr, Gaynes RP, the Project Intensive Care Antimicrobial Resistance (ICARE) Project, and the NNIS System Hospitals: Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002; 8: 702-707.
31. Janknegt R, Wijnands WJA, Caprasse M, Brabdenburg W, Schuitenmaker MG, Stobberingh E: Antimicrobial drug use in hospitals in the Netherlands, Germany and Belgium. Eur J Clin Microbiol Infect Dis 1993; 12: 832-838.
32. Janknegt R, Lashof AO, Gould IM, van der Meer JWM: Antibiotic use in Dutch hospitals 1991-1996. J Antimicrob Chemother 2000; 45: 251-256.
33. Gould IM, Jappy B: Trends in hospital antimicrobial prescribing after nine years of stewardship. J Antimicrob Chemother 2000; 45: 913-917.
34. Floret N, Trouverez M, Thalamy B, Estavoyer JM, Talon D: Evaluation of vancomycin use in a large university-affiliated hospital in eastern France in 1999. Pharm World Sci 2001; 23: 93-97.
35. Bassetti M, di Biagio A, Rebesco B, Cenderello G, Amalfitamo ME, Bassetti D: Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy. Int J Antimicrob Agents 2000; 16: 295-299.
36. GlückT, Linde HJ, Wiegrebe E, Lehn N, Reng M, Schölmerich J: Effects of restrictions on use of vancomycin in a German university hospital. Med Klin 2000; 95: 69-74.
37. Kern WV, Rose AD, Hay B, Muche R, Frank U, and the BadenWürttemberg Interuniversity Study Group: Antimicrobial expenditures and usage at four university hospitals. Infection 2001; 29: 127-137.
38. Kern WV, de With K, Trautmann M, Kern P, Gonnermann C: Glycopeptide use at four university hospitals in southern Germany. Infection 2002; 30: 262-266.
39. WHO Collaborating Centre for Drug Statistics Methodology: ATC classification index with DDDs 2001. Norwegian Institute of Public Health, Oslo.
40. Carling P, Fung T, Coldiron JS: Parenteral antibiotic use in acute care hospitals: a standardized analysis of fourteen institutions. Clin Infect Dis 1999, 29: 1189-1196.
41. Evans ME, Millheim ET, Rapp RP: Vancomycin use in a university medical center: effect of a vancomycin continuation form. Infect Control Hosp Epidemiol 1999; 20: 417-420.
42. Solomon DH, van Houten L, Glynn RJ, Baden L, Curtis K, Schrager HAJ: Academic detailing to improve use of broad-spectrum antibiotics in an academic medical center. Arch Intern Med 2001; 161: 1897-1902.
43. Hamilton CD, Drew R, Janning SW, Latour JK, Hayward S: Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol 2000; 21: 42-45.
44. Misan GM, Martin ED, Smith ER, Somogyi AA, Bartholomeusz RC, Bochner F: Drug utilization review in a teaching hospital: experience with vancomycin. Eur J Clin Pharmacol 1990; 39: 457-461.
45. Nucci M, Landau M, Silveira F, Spector N, Pulcheri W: Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol 2001; 22: 651-653.
46. Zavasky DM, Pestotnik SL, Samore MH, Classen DC, Evans RS, Burke JP: Implementing vancomycin use and monitoring guidelines. Program and Abstracts of the 3gth ICAAC, 1999, San Francisco, American Society for Microbiology, Washington, D.C. 1999, abstr. 187, p 736.
47. Feucht CL, Rice LB: An interventional program to improve antibiotic use. Ann Pharmacother 2003; 37: 646-651.
48. Thomas AR, Cieslak PR, Strausbaugh U, Fleming DW: Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment. Infect Control Hosp Epidemiol 2002; 23: 683-688.
49. Richardson LP, Wiseman SW, Malani PN, Lyons MJ, Kauffman CA: Effectiveness of a vancomycin restriction policy in changing the prescribing patterns of house staff. Microb Drug Resist 2000; 6: 327-330.
50. Walther SM, Erlandsson M, Burman LC, Cars O, Gill H, Hoffman M, Isaksson B, Kahlmeter G, Lindgren S, Nilsson L, Olsson-Liljequist B, Hanberger H; Icustrama Study Group: Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand 2002; 46: 1075-1081.
51. Kern WV: Current epidemiology of infections in neutropenic cancer patients. In: Rolston KVI, Rubenstein EB (eds): Textbook of febrile neutropenia. Martin Dunitz Ltd. London 2001, pp 57-90.
52. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C; International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.Clin Infect Dis 2003; 37: 382-389.
53. Erjavec Z, de Vries-Hospers HC, Laseur M, Halie RM, Daenen S: A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000; 45: 843-849.
54. Koya R, Andersen J, Fernandez H, Goodman M, Spector N, Smith R, Hanlon J, Cassileth PA: Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant 1998; 21: 923-926.
55. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE: Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996; 32A: 1532-1339.
56. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group: Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958. Erratum in: J Infect Dis 1991; 164: 832.